How informed is consent

Slides:



Advertisements
Similar presentations
What does sexual & reproductive health have to do with clinical trials? Providing contraception & reproductive health care helps.
Advertisements

Referral of participants for HIV follow-up care Africa Centre MDP experiences Presented by: Hlengiwe Ndlovu MDP Clinic coordinator.
HIV infection among young people in northwest Tanzania: the role of biological, behavioural and socio-demographic risk factors : randomised controlled.
A. D. Smith, 1 A. Muhaari 2 E. M. van der Elst 2 D. Kowuor, 2 A.Davies, 2 C Agwanda, 1 M. Price, 3 F. Priddy, 3 H. S. Okuku, 2 S.M. Graham, 4 E. J. Sanders.
Attaining Realistic and Substantial Reductions in HIV Incidence: Model Projections of Combining Microbicide and Male Circumcision interventions in Rural.
Contraceptive use and uptake Hasinah Asmal, Samantha Govender, Ian Naicker, Dinesh Singh, Gita Ramjee.
Male circumcision and risk of HIV infection: Current epidemiological data Helen Weiss London School of Hygiene & Tropical Medicine, UK.
Tathmini GBV: Evaluating Comprehensive Gender-Based Violence Program Scale-up in Tanzania Susan Settergren Futures Group.
First Hand Perspective of working on a Microbicides Phase111 Trial Misiwe Mzimela: Social Science Coordinator at Africa Centre.
Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,
Financial Incentives & HIV prevention in Sub-Saharan Africa: Evidence from Three Experimental Interventions Berk Özler & Damien de Walque Development Research.
Long-term impact of a behaviour change intervention among young people in rural Mwanza, Tanzania: Results of a community randomised trial David Ross for.
PREVALENCE OF ANAEMIA IN WOMEN AT SCREENING AND FOLLOW-UP IN A MICROBICIDE PHASE III TRIAL Hasinah Asmal, Dinesh Singh, Gita Ramjee HIV Prevention Research.
Community Engagement in clinical trials Projet Ubuzima experience By Marie Michèle UMULISA Community Outreach & Recruitment Manager, Projet Ubuzima.
Design of Phase III Microbicide Trials: Choice of Control Group August 20, 2003 Rosalie Dominik, DrPH Director of Biostatistics Institute for Family Health.
Access to Care/ Maintenance in Care: Service Needs and Consumer Reported Barriers Angela Aidala, Gunjeong Lee, Brooke West Mailman School of Public Health,
Background Study Objectives Poster No. B50 Track 2  Family planning affects women’s health and lives, and depends on a variety of socio-demographic and.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria Nigerian Canadian Collaboration on AIDS Vaccines (NICCAV) Study Coordinator Discordant Couples.
Mixed methods in medical research Robert Pool Centre for International Health, Hospital Clinic, University of Barcelona London School of Hygiene & Tropical.
Historical Mapping of HIV Programmes 1985 – 2012 in Malawi Presented at the 20 TH INTERNATIONAL AIDS CONFERENCE, MELBOURNE, AUSTRALIA 24 th July 2014 By.
Overview of Microbicide Trials Issues and Challenges.
HIV/AIDS Control in resource- poor settings, or why the ABCs are failing the African Woman: HIV/AIDS Control in resource- poor settings, or why the ABCs.
1 PREVENTION RESEARCH ADVOCACY COMMUNITY PREPAREDNESS IN HIV PREVENTION TRIALS AND USE OF EXISTING METHODOLOGIES MDP 301 trial in Mwanza, Tanzania Charles.
August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.
Challenges of using Urban Heart in Barcelona Carme Borrell.
Montreux, Switzerland, March 2007 New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications New Data on Male Circumcision and.
Microbicides The Population Council Experience and Future Directions Don E. Waldron Medical Director Don E. Waldron Medical Director.
Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
Intravaginal practices in a cohort of women at high risk in North-West Tanzania: Baseline associations with HIV Suzanna Francis, Tony Ao, Joseph Chilongani,
AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Study on Transgender Women’s Health and Well-being in Ho Chi Minh City, Vietnam (TransVN Study) Le.
Rectal microbicides advocacy Issues, work and collaboration Kim Mulji UK rectal microbicides working group.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
XVII Annual International AIDS Conference SHAZ! Shaping the Health of Adolescents in Zimbabwe Mudekunye, S. Laver University of Zimbabwe-University of.
Factors contributing to diaphragm size change in a Clinical Trial HIV PREVENTION RESEARCH UNIT Govender SM; Mtungwa LN; Manarsingh F; Naidoo VH; Ramjee.
Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.
Peer Education Plus (PEP) Model; A Veritable Tool for achieving Behaviour Change. Experience from a Rural Community In Kaduna State, Nigeria AUTHORS: P.
Impact of level of researcher support on coital diary results and acceptability among women at high risk of HIV in the Microbicides Development Programme.
Mycoplasma genitalium and risk of HIV acquisition among women in Zimbabwe Sue Napierala 1, Barbara Van Der Pol 2, Cynthia Kwok 3, Helen Weiss 1, Tsungai.
Microbicides: New Hope for Prevention of HIV and other STIs Your name here
What is HIV research telling us about women’s sexuality? Exploring the construction of sexuality during the Phase III clinical trial of a microbicide gel.
New Developments in Service Delivery: Are GP led Community Based Sexual Health Clinics Acceptable and Satisfactory for Patients Attending? Dr. Seamus Duffy.
E. McLean(1,2), J. Renju(1), J. Wamoyi(3), D. Bukenya(4), W. Ddaaki(5), K. Church(1), B Zaba(1), A. Wringe(1), ALPHA Network 1.London School of Hygiene.
#IAS2017 Increasing HIV test uptake & case finding through assisted HIV partner notification 25 July, 2017 Shona Dalal Department of.
HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.
Getting the FACTS Right!
New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications WHO/UNAIDS Technical Consultation on Male Circumcision and HIV.
Trading sex and building capital: Sexual identity and the programmatic challenge of reaching young African MSM Copyright Colin Purrington (
On behalf of The MTN-020/ASPIRE Study Team
THRIVE Project - Tanzania
Charlotte Watts Gender, Violence and Health Centre
Richard hayes London school of hygiene & Tropical Medicine
MULTIPURPOSE PREVENTION TECHNOLOGY (MPT) PRODUCT PIPELINE & THEIR POTENTIAL ACCEPTABILITY AMONG ADOLESCENT GIRLS & YOUNG WOMEN Barbara Friedland, Population.
Annabelle South MRC Clinical Trials Unit at UCL
Validation of the Sexual Communication Self-Efficacy Scale
By Charles Olusegun DOHERTY
The post-intervention effects of conditional cash transfers for HIV/STI prevention: a randomized trial in rural Tanzania Damien de Walque (The World Bank)
Overview.
MoH leading the design and scale up of PrEP in eswatini
Participant Retention
IMPLEMETNATION OF PrEP IN SRH SETTINGS (OR CLIMBING A MOUNTAIN)
The post-intervention effects of conditional cash transfers for HIV/STI prevention: a randomized trial in rural Tanzania Damien de Walque (The World Bank)
Petchsri Sirinirund Advisor to HIV/AIDS Policy and Programme
Monitoring and Evaluation
Cindy Murray NP Princess Margaret Cancer Centre
Volume 376, Issue 9749, Pages (October 2010)
TRACE INITIATIVE: Risk Factor Questionnaire
Factors associated with the high willingness to use Pre-exposure prophylaxis in female sex workers communities in Kampala, Uganda. Author: Dr. Bashir.
Presentation transcript:

How informed is consent How informed is consent? Using a continuous consent process among high-risk women who engage in transactional sex in the MDP301 vaginal microbicide trial, Mwanza, Tanzania Andrew Vallely1,2, Shelley Lees2,3, Charles Shagi1, Stella Kasindi1, Lisa Vallely3, Selephina Soteli1, Natujwa Kavit1, Sheena McCormack4, Robert Pool5 and Richard J Hayes2 on behalf of the Microbicides Development Programme 1African Medical and Research Foundation, Mwanza, Tanzania; 2London School of Hygiene & Tropical Medicine, London, UK; 3National Institute for Medical Research, Mwanza, Tanzania; 4Medical Research Council Clinical Trials Unit, London, UK; 5Centre for International Health, University of Barcelona, Spain

Objectives To understand the effectiveness of locally-appropriate procedures for obtaining informed consent in the MDP301 phase III vaginal microbicide trial in Tanzania.

Study population An occupational cohort of women who work in bars, restaurants, guesthouses and other food outlets and recreational facilities in Mwanza City, northern Tanzania

Grocery (left) and modern bar (right), Mwanza

Traditional bar (kilabu), Mwanza

Restaurant, Mwanza

Feasibility Study 1573 participants enrolled and FU for up to 18 months; study ran from Jul02-Mar05 High baseline prevalances of HIV, STIs and vaginal infections (e.g. HIV 26%; HSV-2 75%; BV 53%); HIV incidence 3.5/100 PYs Poor education levels and high rates of illiteracy observed (e.g. 24% did not complete primary education) Ref: Vallely A et al; Sex Trans Dis 2007; [E-pub ahead of print]

Continuous consent Experience during feasibility led to re-appraisal of informed consent procedures in consultation with community stakeholders ‘Continuous consent’ combines community and clinic-based components Consent seen as a process from first contact in the community to final visit in the clinic rather than a point activity at study entry

Facility-based mobilisation

Screening & Enrolment Flipchart (groups) Information Sheet Comprehension Checklist Informed Consent Forms Audio-cassette and pictorial directions on gel use (enrolment)

Follow-up visits Audio cassette at any clinic visit as indicated / requested by ppt Comprehension checklist at 12, 24, 40, 52 wk clinic visits

How effective is this approach? In order to understand how well women internalize and retain key messages, in-depth interviews (IDIs) are being carried out in a random sample immediately after their 4, 24 and 52 wk follow-up visits

Results To date (end-Jun07) 104 women have completed IDIs (67x4wk; 30x24wk; 7x52wk) In all interviews there was evidence of good comprehension and retention of key messages e.g. why is the trial being carried out? does the gel protect against HIV?

Why is the trial being carried out? All of the 104 women interviewed had at least a basic understanding of why the trial was being conducted "They are trying the gel so that they may be sure if it will help to prevent infections of HIV/AIDS so that people could start using it.“ “When we went to the clinic they told us that there were two types of gel, there is a gel with medicine and a gel without medicine, now for us that use the gel we do not know if it has medicine or not.”

Does the gel protect against HIV? 81/104 (78%) said that the gel did not protect against HIV “At present I do not know… until after the results are examined by those experts, they will know and will inform us. But I am hopeful that it [gel] can help.”

23/104 (22%) were ‘unsure’ if the gel might be working, reasoning that the trial is on-going “I can’t trust it [the gel] so much since its still on trial” “I am not sure with gel because we haven’t reached the end of the study, we don’t know yet if it protects or not.” “I am not sure [gel works] because it’s on trial…that’s why I use condoms."

Some women in both groups also commented on the gel perhaps having indirect protective effects “I think the gel can protect against infections, maybe…it can even protect against other infections because you don’t get bruises.” “That lubricant [gel] can protect against HIV/AIDS infection because you don’t get bruises… they say that this gel doesn’t have medicine…but that lubricant can prevent you from getting bruises.”

Conclusions Providing information to trial participants in a: focussed, locally-appropriate manner; using methods developed in consultation with the community; and within a continuous informed-consent framework …resulted in high levels of comprehension and message retention in this setting This approach may represent a model for researchers conducting HIV prevention trials among other vulnerable high-risk groups

Acknowledgements Our special thanks go to the women who participated in the feasibility study in Mwanza and those who are currently participating in the MDP301 trial We would also like to acknowledge the contribution and support of the following: Community Advisory Committee (CAC), MDP Mwanza Stakeholders Advisory Group (SAG), MDP Mwanza African Medical & Research Foundation (AMREF) MWAMKO clinical and community teams National Institute for Medical Research (NIMR) Mwanza laboratory, social science, data entry, pharmacy teams